
Molibresib besylate
CAS No. 1895049-20-3
Molibresib besylate( —— )
Catalog No. M32947 CAS No. 1895049-20-3
Molibresib besylate (GSK 525762C) is a selective and potent inhibitor of the bromodomain and extra-terminal (BET) family of proteins with potential anticancer activity for the study of refractory hematologic malignant diseases.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameMolibresib besylate
-
NoteResearch use only, not for human use.
-
Brief DescriptionMolibresib besylate (GSK 525762C) is a selective and potent inhibitor of the bromodomain and extra-terminal (BET) family of proteins with potential anticancer activity for the study of refractory hematologic malignant diseases.
-
DescriptionMolibresib besylate (GSK 525762C; I-BET 762 besylate) is a BET bromodomain inhibitor with IC50 of 32.5-42.5 nM.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayChromatin/Epigenetic
-
TargetEpigenetic Reader Domain
-
RecptorEpigenetic Reader Domain | ROS
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1895049-20-3
-
Formula Weight582.07
-
Molecular FormulaC28H28ClN5O5S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 25 mg/mL (42.95 mM; Ultrasonic )
-
SMILESS(=O)(=O)(O)C1=CC=CC=C1.O(C)C=1C=C2C(N3C([C@H](CC(NCC)=O)N=C2C4=CC=C(Cl)C=C4)=NN=C3C)=CC1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Nicodeme E, et al. Suppression of inflammation by a synthetic histone mimic. Nature. 2010 Dec 23;468(7327):1119-23.?
molnova catalog



related products
-
BY27
BY27, a potent and selective BET BD2 inhibitor (Ki: 3.1 nM) with anticancer activity, inhibits BD1/BD2 of BRD2, BRD3, BRD4, and BRDT, and suppresses tumor growth.
-
TRIM24/BRPF1-IN-2
TRIM24/BRPF1-IN-2 is a selective dual TRIM24/BRPF1 inhibitor with anticancer activity that inhibits proliferation, gene and protein expression, and colony formation of prostate cancer cells in a dose-dependent manner.
-
JQAD1
JQAD1 is a potent and selective histone acetyltransferase EP300 degrader (PROTAC?; DC50≤ 31.6 nM); comprises an EP300 inhibitor, A485, joined by a linker to a cereblon E3 ligase ligand.